COMMUNIQUÉ DE PRESSE publié le 24/01/2024 à 14:00, il y a 2 années 6 mois AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement AiCuris and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to discover new active agents for the treatment and prophylaxis of infections of immunocompromised patients. The partnership aims to develop novel therapies for patients with high medical need. The financial details of the collaboration were not disclosed. For more information, visit www.dzif.de and www.aicuris.com. AiCuris German Center For Infection Research Collaboration License Option Agreement Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 28/09/2023 à 14:00, il y a 2 années 10 mois AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 23/08/2023 à 14:00, il y a 2 années 11 mois AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 14:00, il y a 3 années 1 mois AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 14:00, il y a 3 années 4 mois AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary
Publié le 10/08/2026 à 09:22, il y a 51 minutes Number of shares and voting rights - July 2026 (In French only)
Publié le 10/08/2026 à 09:22, il y a 51 minutes Nombre total d'actions et droits de vote - juillet 2026
Publié le 10/08/2026 à 07:00, il y a 3 heures 14 minutes BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Publié le 10/08/2026 à 07:00, il y a 3 heures 14 minutes Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
Publié le 10/08/2026 à 08:00, il y a 2 heures 14 minutes Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Publié le 10/08/2026 à 08:00, il y a 2 heures 14 minutes Results of AGM and Management Update Presentation
Publié le 07/08/2026 à 23:15, il y a 2 jours 10 heures Faraday Copper Reports Second Quarter 2026 Financial Results
Publié le 07/08/2026 à 23:00, il y a 2 jours 11 heures Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Publié le 10/08/2026 à 09:50, il y a 24 minutes Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Publié le 10/08/2026 à 09:00, il y a 1 heure 13 minutes Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Publié le 10/08/2026 à 09:00, il y a 1 heure 13 minutes Original-Research: Bittium Oyj (von NuWays AG): BUY
Publié le 10/08/2026 à 09:00, il y a 1 heure 14 minutes Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
